» Articles » PMID: 19229374

Brain Metastasis from an Unknown Primary, or Primary Brain Tumour? A Diagnostic Dilemma

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2009 Feb 21
PMID 19229374
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Brain metastasis is increasingly common, affecting 20%-40% of cancer patients. After diagnosis, survival is usually limited to months in these patients. Treatment for brain metastasis includes whole-brain radiation therapy, surgical resection, or both. These treatments aim to slow progression of disease and to improve or maintain neurologic function and quality of life.Although less common, primary brain tumours produce symptoms that are similar to those of brain metastasis. Glioblastoma, the most common malignant tumour of the brain, has a median survival of less than 12 months. Patients are often treated with surgical resection followed by radical radiation therapy and chemotherapy.Here, we present 2 separate cases of lesions in the brain radiologically compatible with brain metastasis. In both cases, no primary cancer site had been established, and neurosurgical intervention was sought to obtain a pathologic diagnosis. Both cases were pathologically confirmed as glioblastoma. These cases demonstrate the importance of differentiation between brain metastases and primary brain tumours to ensure that the appropriate management strategy is implemented.

Citing Articles

Differentiation between glioblastoma and solitary brain metastases using perfusion and amide proton transfer weighted MRI.

Knutsson M, Salomonsson T, Durmo F, Johansson E, Seidemo A, Latt J Front Neurosci. 2025; 19:1533799.

PMID: 39975970 PMC: 11836003. DOI: 10.3389/fnins.2025.1533799.


High-performance presurgical differentiation of glioblastoma and metastasis by means of multiparametric neurite orientation dispersion and density imaging (NODDI) radiomics.

Bai J, He M, Gao E, Yang G, Zhang C, Yang H Eur Radiol. 2024; 34(10):6616-6628.

PMID: 38485749 PMC: 11399163. DOI: 10.1007/s00330-024-10686-8.


Epidermal Growth Factor Receptor Inhibitors in Glioblastoma: Current Status and Future Possibilities.

Ezzati S, Salib S, Balasubramaniam M, Aboud O Int J Mol Sci. 2024; 25(4).

PMID: 38396993 PMC: 10889328. DOI: 10.3390/ijms25042316.


The effects of statin therapy on brain tumors, particularly glioma: a review.

Alrosan A, Heilat G, Al Subeh Z, Alrosan K, Alrousan A, Abu-Safieh A Anticancer Drugs. 2023; 34(9):985-994.

PMID: 37466094 PMC: 10501357. DOI: 10.1097/CAD.0000000000001533.


Radiomics as an emerging tool in the management of brain metastases.

Nowakowski A, Lahijanian Z, Panet-Raymond V, Siegel P, Petrecca K, Maleki F Neurooncol Adv. 2022; 4(1):vdac141.

PMID: 36284932 PMC: 9583687. DOI: 10.1093/noajnl/vdac141.


References
1.
Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M . Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10):2596-606. DOI: 10.1093/brain/awm204. View

2.
Behin A, Hoang-Xuan K, Carpentier A, Delattre J . Primary brain tumours in adults. Lancet. 2003; 361(9354):323-31. DOI: 10.1016/S0140-6736(03)12328-8. View

3.
Schwartz K, Erickson B, Lucchinetti C . Pattern of T2 hypointensity associated with ring-enhancing brain lesions can help to differentiate pathology. Neuroradiology. 2006; 48(3):143-9. DOI: 10.1007/s00234-005-0024-5. View

4.
. Chemotherapy for high-grade glioma. Cochrane Database Syst Rev. 2003; (4):CD003913. PMC: 10625440. DOI: 10.1002/14651858.CD003913. View

5.
Patchell R . The management of brain metastases. Cancer Treat Rev. 2003; 29(6):533-40. DOI: 10.1016/s0305-7372(03)00105-1. View